|
See related Glucophage XR extended-release tab information |
|
|
|
Manufacturer |
Merck Serono |
|
Distributor |
Hong Kong: Zuellig |
|
Contents |
Metformin HCl |
|
Indications |
Treatment of type 2 DM in adults as an adjunct to adequate diet & exercise. Monotherapy or in combination w/ other oral antidiabetic medicines or insulin.
Click to view Glucophage XR detailed prescribing infomation |
|
Dosage |
Adult Initially 1 tab daily w/ evening meal. After 10-15 days, may increase at increments of 500 or 750 mg depending on blood glucose measurements. Max: Four 500-mg tab or three 750-mg tab or two 1,000-mg tab daily.
Click to view Glucophage XR detailed prescribing infomation |
|
Overdosage |
View Glucophage XR overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food (Swallow whole, do not chew/crush.). |
|
Contraindications |
Ketoacidosis or pre-coma, renal or hepatic insufficiency, infectious diseases, following an IV urography or angiography, heart failure, recent MI, resp insufficiency, shock, persistent or severe diarrhoea, recurrent vomiting, alcoholism. Lactation.
Click to view Glucophage XR detailed prescribing infomation |
|
Special Precautions |
Regular renal & blood sugar monitoring. Suspend therapy during surgery & clinical investigations. May impair ability to drive or operate machinery in combination w/ other antidiabetic agents. Pregnancy.
Click to view Glucophage XR detailed prescribing infomation |
|
Adverse Drug Reactions |
GI & taste disturbances.
View ADR Monitoring Form |
|
Drug Interactions |
Iodinated contrast agents, corticosteroids, NSAIDs, ACE inhibitors, diuretics, β2-agonists, alcohol.
View more drug interactions with Glucophage XR |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Glucophage XR storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Glucophage XR description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Glucophage XR mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
